Live Breaking News & Updates on Massachusetts Based Constellation Pharmaceuticals

Stay updated with breaking news from Massachusetts based constellation pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

'Challenging Market' Leads MorphoSys to Cut Preclinical R&D, Turn Focus to Cancer

MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck. ....

United Kingdom , Jean Paul Kress , Constellation Pharmaceuticals , Germany Based Morphosys , Massachusetts Based Constellation Pharmaceuticals , Paul Kress , Sierra Oncology , Imago Biosciences , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery ,

What If Scientists Shared Their Reagents for Free?

Some researchers have decided to provide their products without financial compensation or expectations of authorship on resulting papers, prompting a flurry of new work. ....

Harvard University , United States , Dana Farber Cancer Institute , Jay Bradner , Ross Levine , Alexandre Bisson , Matthew Bogyo , Luke Lavis , John Janetzko , Sloan Kettering Levine , Hermen Overkleeft , Adam Cohen , Broad Institute , Novartis Institutes For Biomedical Research , Brandeis University , Howard Hughes Medical Institute Janelia Research Campus , Leiden University , Development Of Therapeutics , Constellation Pharmaceuticals , Memorial Sloan Kettering Cancer Center , Massachusetts Based Constellation Pharmaceuticals , Novartis Institutes , Biomedical Research , Howard Hughes Medical Institute , Janelia Research , Stanford Medicine ,

MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs

MorphoSys is cutting the drug discovery and R&D work of Constellation Pharmaceuticals, a company it acquired lats year in a $1.7 billion deal. This consolidation of research operations will result in non-cash impairment charge on Constellation’s goodwill. ....

United Kingdom , Jean Paul Kress , Constellation Pharmaceuticals , Massachusetts Based Constellation Pharmaceuticals , Paul Kress , Sys Chief Financial Officer Sung Lee , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Ealth And Wellness , Mployee Wellness Programs ,